George Farmer
Stock Analyst at Scotiabank
(2.20)
# 2,853
Out of 5,044 analysts
72
Total ratings
47.5%
Success rate
-3.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $1.38 | +624.64% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $87.49 | +52.02% | 4 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $1.82 | -67.03% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $20.18 | +132.90% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $13.51 | +25.83% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $5.09 | +135.76% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $10.89 | -17.36% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune | Maintains: Sector Outperform | $3.15 → $1.4 | $0.06 | +2,317.96% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $29.76 | +37.77% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $36.14 | +43.88% | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $78 → $80 | $53.49 | +49.56% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $149.13 | +50.20% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $34.93 | +192.01% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $10.51 | -4.85% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $836.39 | -14.51% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $6.37 | +261.07% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $1.56 | +1,182.05% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $32.57 | +133.34% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $4.40 | +195.45% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $25.35 | +329.98% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $91.65 | -5.07% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.58 | +1,179.07% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.84 | +4,662.47% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $40.08 | -32.63% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $1.38
Upside: +624.64%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $87.49
Upside: +52.02%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $1.82
Upside: -67.03%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $20.18
Upside: +132.90%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $13.51
Upside: +25.83%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $5.09
Upside: +135.76%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $10.89
Upside: -17.36%
Adaptimmune
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.06
Upside: +2,317.96%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $29.76
Upside: +37.77%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $36.14
Upside: +43.88%
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $53.49
Upside: +49.56%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $149.13
Upside: +50.20%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $34.93
Upside: +192.01%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $10.51
Upside: -4.85%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $836.39
Upside: -14.51%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $6.37
Upside: +261.07%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $1.56
Upside: +1,182.05%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $32.57
Upside: +133.34%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $4.40
Upside: +195.45%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $25.35
Upside: +329.98%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $91.65
Upside: -5.07%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.58
Upside: +1,179.07%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.84
Upside: +4,662.47%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $40.08
Upside: -32.63%